Monteris touts laser ablation study data

Monteris Medical said yesterday that data from a new study of its NeuroBlate minimally invasive robotic laser thermotherapy tool showed improved outcomes for patients undergoing procedures with the device. The findings were presented at the Congress of Neurological Surgeons annual meeting in New Orleans. The NeuroBlate system is an FDA-cleared device designed to ablate, necrotize or coagulate soft tissue during neurosurgery procedures through laser thermotherapy, and is not intended for any specific disease or lesion type, the company said. “To date, limited data have been available on brain tumor patients that received MRI-guided laser ablation. This multicenter study, which also included cases from Washington University in Saint Louis and Yale-New Haven Hospital, is the largest series of laser ablation for patients with newly diagnosed glioblastoma lesions ever conducted and shows that NeuroBlate has an impact on both overall and progression-free survival on patients after surgery. While additional prospective studies are warranted, these preliminary findings are encouraging,” neurosurgeon Dr. Alireza Mohammadi said in prepared remarks. A study of the device, used to treat glioblastomas in 22 patients who had not received prior radiation or chemotherapy, found extent of coverage for 10-minute and 2 minute thermal-damage procedures to be 91% and 94%, respectively. In a separate study, the New Orleans-based company said the NeuroBlate SideFire directional las...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Neurological Surgical Monteris Medical Source Type: news